Home › Compare › TPLKF vs ABBV
TPLKF yields 5.92% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, TPLKF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TPLKF + ABBV for your $10,000?
PVA TePla AG, together with its subsidiaries, manufactures and sells systems for the production and refinement of high-tech materials worldwide. It operates through two segments, Industrial Systems and Semiconductor Systems. The Industrial Systems division provides structural material technologies for semiconductor, aviation and aerospace, energy technology, and hard metal tools industries; and engages in the vacuum brazing, vacuum heat treatment, and diffusion bonding activities. The Semiconductor Systems division offers crystal growing systems, including silicon wafer technologies for microelectronics and silicon carbide wafer technologies for high-performance electronics; metrology systems comprising technologies for non-destructive quality control of wafers, semiconductor parts, and high-tech industrial material; and plasma systems, such as production technologies for micro-electronic mechanical systems and high-brightness light-emitting diodes, as well as technologies for the fabrication of ultrathin wafers. The company is headquartered in Wettenberg, Germany.
Full TPLKF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.